Five-day infusion fluorouracil plus vinorelbine in women with breast cancer previously treated with anthracyclines and paclitaxel

Breast Cancer Research and Treatment

Volumn 62, Issue 2, 2000, Pages 135-139

  Zambetti, M ^a   Mariani, G ^a   Demicheli, R ^a   Verderio, P ^a   Potepan, P ^a   Garbagnati, F ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Metastatic breast cancer; Second line chemotherapy

Indexed keywords

ANTHRACYCLINE DERIVATIVE; FLUOROURACIL; NAVELBINE; PACLITAXEL;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALLERGIC REACTION; ARTICLE; BONE MARROW TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; DRUG CHOICE; DRUG EFFICACY; EMBOLISM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; STOMATITIS;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; TREATMENT OUTCOME; VINBLASTINE;

EID: 0033821811     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006445713773     Document Type: Article

References (13)

1. Low dose continous infusion 5-fluorouracil
2. 5-Fluorouracil rechallenge by pretreated infusion in metastatic breast cancer
3. Optimal schedule for 5-fluorouracil chemotherapy: Intermittent bolus or continuous infusion
4. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy
5. Vinorelbine: An active non cross-resistant drug in advanced breast cancer. Results from a phase II study
6. Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients
7. Efficacy and tolerance of vinorelbine and fluorouracil combination as first-line chemotherapy of advanced breast cancer. Results of a phase II study using a sequential group method
8. Vinorelbine and protracted infusional 5-fluorouracil is a very active and manageable schema for heavily pretreated advanced breast cancer patients
9. Phase I-II study of vinorelbine in combination with 5-fluorouracil and folinic acid as first-line chemotherapy in metastatic breast cancer: A regimen with a low subjective toxic burden
10. Preliminary studies of a novel oral fluoropyrimidine carbamate: Capecitabine
11. A multicentric phase II trial of Xeloda (capecitabine) in paclitaxel refractory breast cancer
12. Phase I clinical and pharmacological study of eniluracil plus fluorouracil in patients with advanced cancer
13. Pharmacokinetic, oral bioavability and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase